There are currently 695 clinical trials in Orlando, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including AdventHealth Orlando, GSK Investigational Site, Orlando Clinical Research Center and Nemours Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
NCT06075095
Recruiting
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of: A screening and placebo run-in period of approximately 2 weeks prior to first dosing Three treatment periods of approximately 4 weeks each (one period for ea... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
06/13/2024
Locations: Research Site, Orlando, Florida
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
NCT05627557
Recruiting
This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
Gender:
All
Ages:
Between 2 years and 25 years
Trial Updated:
06/13/2024
Locations: Nemours Children's Hospital, Orlando, Florida
Conditions: Childhood Idiopathic Nephrotic Syndrome
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06058013
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Neumora Investigator Site, Orlando, Florida +1 locations
Conditions: Major Depressive Disorder
Register for Updates
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
NCT06021522
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to [>=] 6 and less than [<] 12 years of age), adolescents (>=12 and <18 years of age), and adults (>=18 years of age) with Tourette's Syndrome (TS).
Gender:
All
Ages:
6 years and above
Trial Updated:
06/13/2024
Locations: APG Research, LLC, Orlando, Florida
Conditions: Tourette Syndrome
Register for Updates
Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426
Recruiting
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Neumora Investigator Site, Orlando, Florida
Conditions: Major Depressive Disorder
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Research Site, Orlando, Florida
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this ext... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Neumora Investigator Site, Orlando, Florida
Conditions: Major Depressive Disorder
Register for Updates
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
NCT05502341
Recruiting
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Orlando Immunology Center, Orlando, Florida +1 locations
Conditions: HIV-1-infection
Register for Updates
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
NCT05785715
Recruiting
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: Orlando Health, Inc., Orlando, Florida
Conditions: Ulcerative Colitis
Register for Updates
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT05839041
Recruiting
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/13/2024
Locations: Florida Retina Institute, Orlando, Florida
Conditions: Geographic Atrophy of the Macula, Macular Degeneration
Register for Updates
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671
Recruiting
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/13/2024
Locations: Clinical Study Site, Orlando, Florida
Conditions: Inflammatory Bowel Diseases, Colitis, Ulcerative
Register for Updates
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
NCT05935033
Recruiting
The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic impairment relative to matched participants with normal hepatic function.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: Orlando, Florida, Orlando, Florida
Conditions: Hepatic Impairment
Register for Updates